Development and validation of UHPLC–MS/MS methods for the quantification of colistin in plasma and dried plasma spots

Research output: Contribution to journalArticle

Abstract

Quantification of colistin in plasma samples may be very useful in optimizing therapy especially in special patients’ population. Nevertheless, therapeutic drug monitoring of colistin is still limited probably for the low number of laboratories which perform this analysis and for high shipment costs. We developed and validated new UHPLC–MS/MS methods to quantify colistin in plasma and in dried plasma spots (DPS) collected on dried sample spots devices (DSSD). Colistin A, Colistin B and polimixin B, used as internal standard, were detected using multiple reaction monitoring (MRM) of the following specific transitions: 585.5 → 534.9; 576, 578.5 → 527.9; 568.9 and 602.5 → 100.9, 551.9, 592.8, respectively. Colistin A and B were extracted from plasma using protein precipitation and from DSSD using an extraction basic solution. Both methods were validated, and the mean intra and inter-day accuracies and precisions were in accordance with FDA and EMA guidelines. Colistin in DPS was found to be stable for at least one week at room temperature (20–25 °C). A statistically significant linear correlation was found between colistin extracted from plasma and from DPS [r2 0.9864 (P < 0.0001, 95% CI 0.9699–0.9939) for colistin A and 0.9695 (P < 0.0001, 95% CI 0.9310–0.9866) for colistin B, respectively]. DPS on DSSD represents a safe and cheap strategy to store and ship at room temperature plasma samples. Thus, it is suited for pharmacokinetic studies and therapeutic drug monitoring of colistin.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume129
DOIs
Publication statusPublished - Sep 10 2016

Fingerprint

Colistin
Plasmas
Drug Monitoring
Equipment and Supplies
Monitoring
Temperature
Pharmacokinetics
Ships
Pharmaceutical Preparations
Blood Proteins

Keywords

  • Colistin
  • Dried blood spots
  • Dried plasma spot
  • LC–MS
  • Therapeutic drug monitoring
  • UHPLC–MS/MS

ASJC Scopus subject areas

  • Analytical Chemistry
  • Medicine(all)
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Cite this

@article{ef65536667da4b40b6557b7194c1a4ca,
title = "Development and validation of UHPLC–MS/MS methods for the quantification of colistin in plasma and dried plasma spots",
abstract = "Quantification of colistin in plasma samples may be very useful in optimizing therapy especially in special patients’ population. Nevertheless, therapeutic drug monitoring of colistin is still limited probably for the low number of laboratories which perform this analysis and for high shipment costs. We developed and validated new UHPLC–MS/MS methods to quantify colistin in plasma and in dried plasma spots (DPS) collected on dried sample spots devices (DSSD). Colistin A, Colistin B and polimixin B, used as internal standard, were detected using multiple reaction monitoring (MRM) of the following specific transitions: 585.5 → 534.9; 576, 578.5 → 527.9; 568.9 and 602.5 → 100.9, 551.9, 592.8, respectively. Colistin A and B were extracted from plasma using protein precipitation and from DSSD using an extraction basic solution. Both methods were validated, and the mean intra and inter-day accuracies and precisions were in accordance with FDA and EMA guidelines. Colistin in DPS was found to be stable for at least one week at room temperature (20–25 °C). A statistically significant linear correlation was found between colistin extracted from plasma and from DPS [r2 0.9864 (P < 0.0001, 95{\%} CI 0.9699–0.9939) for colistin A and 0.9695 (P < 0.0001, 95{\%} CI 0.9310–0.9866) for colistin B, respectively]. DPS on DSSD represents a safe and cheap strategy to store and ship at room temperature plasma samples. Thus, it is suited for pharmacokinetic studies and therapeutic drug monitoring of colistin.",
keywords = "Colistin, Dried blood spots, Dried plasma spot, LC–MS, Therapeutic drug monitoring, UHPLC–MS/MS",
author = "Giuliana Cangemi and Sebastiano Barco and Elio Castagnola and Gino Tripodi and Fabio Favata and Antonio D'Avolio",
year = "2016",
month = "9",
day = "10",
doi = "10.1016/j.jpba.2016.08.002",
language = "English",
volume = "129",
pages = "1--7",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

TY - JOUR

T1 - Development and validation of UHPLC–MS/MS methods for the quantification of colistin in plasma and dried plasma spots

AU - Cangemi, Giuliana

AU - Barco, Sebastiano

AU - Castagnola, Elio

AU - Tripodi, Gino

AU - Favata, Fabio

AU - D'Avolio, Antonio

PY - 2016/9/10

Y1 - 2016/9/10

N2 - Quantification of colistin in plasma samples may be very useful in optimizing therapy especially in special patients’ population. Nevertheless, therapeutic drug monitoring of colistin is still limited probably for the low number of laboratories which perform this analysis and for high shipment costs. We developed and validated new UHPLC–MS/MS methods to quantify colistin in plasma and in dried plasma spots (DPS) collected on dried sample spots devices (DSSD). Colistin A, Colistin B and polimixin B, used as internal standard, were detected using multiple reaction monitoring (MRM) of the following specific transitions: 585.5 → 534.9; 576, 578.5 → 527.9; 568.9 and 602.5 → 100.9, 551.9, 592.8, respectively. Colistin A and B were extracted from plasma using protein precipitation and from DSSD using an extraction basic solution. Both methods were validated, and the mean intra and inter-day accuracies and precisions were in accordance with FDA and EMA guidelines. Colistin in DPS was found to be stable for at least one week at room temperature (20–25 °C). A statistically significant linear correlation was found between colistin extracted from plasma and from DPS [r2 0.9864 (P < 0.0001, 95% CI 0.9699–0.9939) for colistin A and 0.9695 (P < 0.0001, 95% CI 0.9310–0.9866) for colistin B, respectively]. DPS on DSSD represents a safe and cheap strategy to store and ship at room temperature plasma samples. Thus, it is suited for pharmacokinetic studies and therapeutic drug monitoring of colistin.

AB - Quantification of colistin in plasma samples may be very useful in optimizing therapy especially in special patients’ population. Nevertheless, therapeutic drug monitoring of colistin is still limited probably for the low number of laboratories which perform this analysis and for high shipment costs. We developed and validated new UHPLC–MS/MS methods to quantify colistin in plasma and in dried plasma spots (DPS) collected on dried sample spots devices (DSSD). Colistin A, Colistin B and polimixin B, used as internal standard, were detected using multiple reaction monitoring (MRM) of the following specific transitions: 585.5 → 534.9; 576, 578.5 → 527.9; 568.9 and 602.5 → 100.9, 551.9, 592.8, respectively. Colistin A and B were extracted from plasma using protein precipitation and from DSSD using an extraction basic solution. Both methods were validated, and the mean intra and inter-day accuracies and precisions were in accordance with FDA and EMA guidelines. Colistin in DPS was found to be stable for at least one week at room temperature (20–25 °C). A statistically significant linear correlation was found between colistin extracted from plasma and from DPS [r2 0.9864 (P < 0.0001, 95% CI 0.9699–0.9939) for colistin A and 0.9695 (P < 0.0001, 95% CI 0.9310–0.9866) for colistin B, respectively]. DPS on DSSD represents a safe and cheap strategy to store and ship at room temperature plasma samples. Thus, it is suited for pharmacokinetic studies and therapeutic drug monitoring of colistin.

KW - Colistin

KW - Dried blood spots

KW - Dried plasma spot

KW - LC–MS

KW - Therapeutic drug monitoring

KW - UHPLC–MS/MS

UR - http://www.scopus.com/inward/record.url?scp=84982845036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982845036&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2016.08.002

DO - 10.1016/j.jpba.2016.08.002

M3 - Article

AN - SCOPUS:84982845036

VL - 129

SP - 1

EP - 7

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -